Class Action Filed Against ESSA Pharma Inc. (EPIX) Seeking Recovery for Investors

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from December 12, 2023, to October 31, 2024 [3]. - Allegations include that the defendants made materially false and misleading statements about masofaniten's efficacy, claiming it had no clear benefit over enzalutamide alone [3]. - It is asserted that the M-E Combination Study was unlikely to meet its primary endpoint, leading to overstated clinical and commercial prospects for masofaniten [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by March 25, 2025, to potentially become lead plaintiffs [4]. - Registration will provide shareholders with updates throughout the case lifecycle, and participation incurs no cost or obligation [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, emphasizing responsible business practices [5].